Results 251 to 260 of about 4,995,094 (293)

Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7

Cell Chemical Biology, 2019
Dongxu Li, Kenneth H Pearce, Huitao Fan
exaly  

Identification of dual role of piperazine-linked phenyl cyclopropyl methanone as positive allosteric modulator of 5-HT and negative allosteric modulator of 5-HT receptors

European Journal of Medicinal Chemistry, 2019
Mohammad Imran Siddiqi, Prem N Yadav, Ajeet Kumar   +2 more
exaly  

MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate

ACS Medicinal Chemistry Letters, 2018
Douglas Beshore, William J. Ray, Mark T Bilodeau   +2 more
exaly  

Pharmacological characterisation of MDI-222, a novel AMPA receptor positive allosteric modulator with an improved safety profile

Journal of Psychopharmacology, 2020
John Atack, Simon E Ward
exaly  

Functional properties and mechanism of action of PPTQ, an allosteric agonist and low nanomolar positive allosteric modulator at GABA receptors

Biochemical Pharmacology, 2018
Anders A Jensen, Nawid Madjroh
exaly  

Positive allosteric modulators (PAM)

2011
GREEN LUKE, GUBA WOLFGANG, JAESCHKE GEORG, JOLIDON SYNESE, LINDEMANN LOTHAR, RICCI ANTONIO, RUEHER DANIEL, STADLER HEINZ, VIEIRA ERIC   +8 more
openaire   +3 more sources

Quinolizidinone M1 receptor positive allosteric modulators

2009
KUDUK SCOTT D, CHANG RONALD K
openaire   +12 more sources

POSITIVE ALLOSTERIC MODULATORS OF MGLUR2

2012
DUDKIN VADIM, FRALEY MARK E, ARRINGTON KENNETH L, LAYTON MARK E, RODZINAK KEVIN J, PERO JOSEPH E, REIF ALEXANDER J   +6 more
openaire   +5 more sources

An orally bioavailable positive allosteric modulator of the mGlu receptor with efficacy in an animal model of motor dysfunction

Bioorganic and Medicinal Chemistry Letters, 2010
Bastian Hengerer, Ralf Heilker, Mark J Gemkow   +2 more
exaly  

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial

Lancet, The, 2022
exaly